{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T23:10:28Z","timestamp":1768518628763,"version":"3.49.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"DOI":"10.1186\/s12959-025-00821-w","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:34:59Z","timestamp":1767843299000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Characterization of anticoagulated patients in a Latin American country: indications, treatment patterns, and complications"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2151-0722","authenticated-orcid":false,"given":"Sebasti\u00e1n","family":"Seni-Molina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7638-1119","authenticated-orcid":false,"given":"Arturo D.","family":"Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8219-9285","authenticated-orcid":false,"given":"Valeria","family":"Azcarate-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1278-8943","authenticated-orcid":false,"given":"Juan Andr\u00e9s","family":"Mu\u00f1oz-Ordo\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8854-105X","authenticated-orcid":false,"given":"Hoover O.","family":"Le\u00f3n-Giraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Skarlett","family":"Estupi\u00f1an","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6287-7671","authenticated-orcid":false,"given":"Ana Cristina","family":"Montenegro-Arenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0024-6038","authenticated-orcid":false,"given":"Jes\u00fas","family":"Arguello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-915X","authenticated-orcid":false,"given":"Dora Ines","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3453-9605","authenticated-orcid":false,"given":"Fernando Rivera","family":"Toquica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rubiela Ardilla","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5867-2876","authenticated-orcid":false,"given":"Juli\u00e1n","family":"Lugo-Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4312-177X","authenticated-orcid":false,"given":"Juan Alberto","family":"Ceron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jhon Ubeimar","family":"Cata\u00f1o-Bedoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5123-7283","authenticated-orcid":false,"given":"Gilberto Amed","family":"Castillo-Barrios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6635-6224","authenticated-orcid":false,"given":"Juan Esteban","family":"G\u00f3mez-Mesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the RECCANT Research Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"9859","key":"821_CR1","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095\u2013128.","journal-title":"Lancet"},{"issue":"Suppl 3","key":"821_CR2","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.21037\/cdt.2017.11.08","volume":"7","author":"R Oklu","year":"2017","unstructured":"Oklu R, Thrombosis. Cardiovasc Diagn Ther. 2017;7(Suppl 3):S131\u20133.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"10440","key":"821_CR3","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/S0140-6736(24)00769-4","volume":"403","author":"Murray","year":"2024","unstructured":"Murray CJL, GBD 2021 Collaborators. Findings from the global burden of disease study 2021. Lancet Lond Engl. 2024;403(10440):2259\u201362.","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"821_CR4","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.3390\/jcm14051647","volume":"14","author":"A Kholmukhamedov","year":"2025","unstructured":"Kholmukhamedov A, Subbotin D, Gorin A, Ilyassov R. Anticoagulation management: current landscape and future trends. J Clin Med. 2025;14(5):1647.","journal-title":"J Clin Med"},{"key":"821_CR5","unstructured":"Amaraneni A, Chippa V, Goldin J, Rettew AC. Anticoagulation Safety. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 July 3]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519025\/"},{"key":"821_CR6","doi-asserted-by":"crossref","unstructured":"Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol 2008 June 1;141(6):757\u201363.","DOI":"10.1111\/j.1365-2141.2008.07119.x"},{"issue":"5","key":"821_CR7","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/ATVBAHA.115.303397","volume":"35","author":"CH Yeh","year":"2015","unstructured":"Yeh CH, Hogg K, Weitz JI. Overview of the new oral anticoagulants. Arterioscler Thromb Vasc Biol. 2015;35(5):1056\u201365.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"821_CR8","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/pds.5124","volume":"30","author":"JE Machado-Alba","year":"2021","unstructured":"Machado-Alba JE, Gaviria-Mendoza A, Machado-Duque ME, Tovar-Yepes C, Ruig\u00f3mez A, Garc\u00eda Rodr\u00edguez LA. Use of non-vitamin K antagonist oral anticoagulants in Colombia: a descriptive study using a National administrative healthcare database. Pharmacoepidemiol Drug Saf. 2021;30(4):426\u201334.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"821_CR9","doi-asserted-by":"crossref","unstructured":"Laverde LP, G\u00f3mez SE, Montenegro AC, Lineros A, Wills B, Buitrago AF. Experiencia de Una cl\u00ednica de anticoagulaci\u00f3n. Rev Colomb Cardiol. 2015 Sept;22(5):224\u201330.","DOI":"10.1016\/j.rccar.2015.04.008"},{"key":"821_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/VHRM.S391549","volume":"19","author":"ME Machado-Duque","year":"2023","unstructured":"Machado-Duque ME, Gaviria-Mendoza A, Reyes JM, Mesa A, Casta\u00f1o-Gamboa N, Valladales-Restrepo LF, et al. Clinical Characteristics, patterns of Use, and incidence of adverse events in patients with nonvalvular atrial fibrillation treated with oral anticoagulants in Colombia. Vasc Health Risk Manag. 2023;19:157\u201367.","journal-title":"Vasc Health Risk Manag"},{"key":"821_CR11","doi-asserted-by":"crossref","unstructured":"Gil-Aldana VJ, Jim\u00e9nez-Lizcano AM, Su\u00e1rez-Ram\u00edrez \u00d3F, Vera-Le\u00f3n CC, Torres-Dimas AE. Nonvalvular atrial fibrillation in anticoagulated patients. Acta Med Colomb. 2022 Sept;47(3):1.","DOI":"10.36104\/amc.2022.2202"},{"issue":"4","key":"821_CR12","first-page":"353","volume":"28","author":"A Montenegro","year":"2021","unstructured":"Montenegro A, Plaza M, \u00c1lvarez R, Pinto A, G\u00f3mez L, Casta\u00f1o J, et al. Characteristics of patients in two anticoagulation clinics in Colombia. Rev Colomb Cardiol. 2021;28(4):353\u20139.","journal-title":"Rev Colomb Cardiol"},{"issue":"2","key":"821_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.30789\/rcneumologia.v32.n2.2020.531","volume":"32","author":"O Saenz","year":"2020","unstructured":"Saenz O, Sanabria F, Rubio AM, Gonz\u00e1lez F, Gamba N. Cl\u00ednica de anticoagulaci\u00f3n de La subred Centro Oriente, En Bogot\u00e1. Rev Colomb Neumol. 2020;32(2):37\u201345.","journal-title":"Rev Colomb Neumol"},{"key":"821_CR14","doi-asserted-by":"crossref","unstructured":"Kohn CO, Ortiz OH, Franco CJV, Acosta LIT, Restrepo FAM. La cl\u00ednica de anticoagulaci\u00f3n Del hospital universitario San Vicente de Pa\u00fal: demograf\u00eda, efectividad y complicaciones. Iatreia. 2004;17(2):\u2013g.","DOI":"10.17533\/udea.iatreia.4047"},{"issue":"4","key":"821_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.36104\/amc.2013.114","volume":"38","author":"LB Taboada","year":"2013","unstructured":"Taboada LB, Silva LE, Montenegro AC. Beneficios de La cl\u00ednica de anticoagulaci\u00f3n. Acta Med Colomb. 2013;38(4):239\u201343.","journal-title":"Acta Med Colomb"},{"issue":"6","key":"821_CR16","first-page":"379","volume":"31","author":"S Seni-Molina","year":"2025","unstructured":"Seni-Molina S, Mora AD, Guti\u00e9rrez-Posso J, \u00d1\u00e1\u00f1ez M, Victoria- Salcedo JD, D\u00edez-Sep\u00falveda J, et al. Registro Colombiano de cl\u00ednicas de anticoagulaci\u00f3n (RECCANT) y El Uso de agentes reversores (RECCANT-AR): justificaci\u00f3n y dise\u00f1o. Rev Colomb Cardiol. 2025;31(6):379\u201388.","journal-title":"Rev Colomb Cardiol"},{"issue":"5","key":"821_CR17","doi-asserted-by":"publisher","first-page":"e0124719","DOI":"10.1371\/journal.pone.0124719","volume":"10","author":"E Antonucci","year":"2015","unstructured":"Antonucci E, Poli D, Tosetto A, Pengo V, Tripodi A, Magrini N, et al. The Italian START-Register on anticoagulation with focus on atrial fibrillation. PLoS ONE. 2015;10(5):e0124719.","journal-title":"PLoS ONE"},{"issue":"10","key":"821_CR18","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s12471-016-0874-y","volume":"24","author":"V ten Cate","year":"2016","unstructured":"ten Cate V, ten Cate H, Verheugt FWA. The global anticoagulant registry in the FIELD-Atrial fibrillation (GARFIELD-AF). Neth Heart J. 2016;24(10):574\u201380.","journal-title":"Neth Heart J"},{"issue":"1","key":"821_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1471-2261-13-31","volume":"13","author":"PN Apenteng","year":"2013","unstructured":"Apenteng PN, Murray ET, Holder R, Hobbs FDR, Fitzmaurice DA, UK GARFIELD Investigators and GARFIELD Steering Committee. An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol. BMC Cardiovasc Disord. 2013;13(1):31.","journal-title":"BMC Cardiovasc Disord"},{"issue":"11","key":"821_CR20","doi-asserted-by":"publisher","first-page":"e033283","DOI":"10.1136\/bmjopen-2019-033283","volume":"9","author":"F Dalgaard","year":"2019","unstructured":"Dalgaard F, Pieper K, Verheugt F, Camm AJ, Fox KA, Kakkar AK, et al. GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study. BMJ Open. 2019;9(11):e033283.","journal-title":"BMJ Open"},{"issue":"5","key":"821_CR21","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3390\/healthcare11050638","volume":"11","author":"LG Mantovani","year":"2023","unstructured":"Mantovani LG, Cozzolino P, Ferrara P, Virdone S, Camm AJ, Verheugt FWA, et al. Healthcare resource utilization in patients with newly diagnosed atrial fibrillation: A global analysis from the GARFIELD-AF registry. Healthcare. 2023;11(5):638.","journal-title":"Healthcare"},{"issue":"Suppl1","key":"821_CR22","first-page":"A13772","volume":"144","author":"J Seelig","year":"2021","unstructured":"Seelig J, Trinks-Roerdink EM, Chu G, Pisters R, de Vries TA, Ten Cate H, et al. Abstract 13772: anticoagulation guideline adherence in 4,500 patients with newly diagnosed atrial fibrillation: insights from the prospective DUTCH-AF registry. Circulation. 2021;144(Suppl1):A13772\u201313772.","journal-title":"Circulation"},{"issue":"8","key":"821_CR23","doi-asserted-by":"publisher","first-page":"e036220","DOI":"10.1136\/bmjopen-2019-036220","volume":"10","author":"G Chu","year":"2020","unstructured":"Chu G, Seelig J, Trinks-Roerdink EM, van Alem AP, Alings M, van den Bemt B, et al. Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation. BMJ Open. 2020;10(8):e036220.","journal-title":"BMJ Open"},{"issue":"2","key":"821_CR24","doi-asserted-by":"publisher","first-page":"e038448","DOI":"10.1161\/JAHA.124.038448","volume":"14","author":"SHM Lam","year":"2025","unstructured":"Lam SHM, Romiti GF, Corica B, Bucci T, Olshansky B, Chao T, et al. Number of previous strokes and the association with clinical outcomes of patients with atrial fibrillation: longitudinal data from the GLORIA-AF registry. J Am Heart Assoc. 2025;14(2):e038448.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"821_CR25","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.ahj.2013.12.006","volume":"167","author":"MV Huisman","year":"2014","unstructured":"Huisman MV, Lip GYH, Diener HC, Dubner SJ, Halperin JL, Ma CS, et al. Design and rationale of global registry on Long-Term oral antithrombotic treatment in patients with atrial fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. Am Heart J. 2014;167(3):329\u201334.","journal-title":"Am Heart J"},{"key":"821_CR26","doi-asserted-by":"crossref","unstructured":"Cohen O, Waldman Radinsky L, Kenet G, Mah\u00e9 I, Barillari G, Soler S et al. Venous thromboembolism characteristics and outcomes among RIETE patients tested and untested for inherited thrombophilia. Blood Adv 2024 Sept 24;8(18):4950\u20139.","DOI":"10.1182\/bloodadvances.2024012611"},{"issue":"3","key":"821_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.arbres.2021.06.010","volume":"58","author":"M Monreal","year":"2022","unstructured":"Monreal M, Jim\u00e9nez D, Bikdeli B. RIETE registry: Past, present and future. Arch Bronconeumol. 2022;58(3):205\u20137.","journal-title":"Arch Bronconeumol"},{"key":"821_CR28","doi-asserted-by":"crossref","unstructured":"Tafur AJ, Brenner B, Demelo-Rodr\u00edguez P, Guirado L, Pedrajas JM, Mazzolai L et al. Venous thromboembolism outcomes by geographic region and self-reported race: insights from the RIETE registry. Thromb Haemost. 2025 June 24.","DOI":"10.1055\/a-2615-4591"},{"key":"821_CR29","unstructured":"GARFIELD-VTE Registry. About GARFIELD-VTE [Internet]. 2025 [cited 2025 Jun 28]. Available from: https:\/\/vte.garfieldregistry.org\/about\/about-garfield-vte"},{"issue":"2","key":"821_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1055\/s-0038-1676611","volume":"119","author":"W Ageno","year":"2019","unstructured":"Ageno W, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, et al. Characteristics and management of patients with venous thromboembolism: the GARFIELD-VTE registry. Thromb Haemost. 2019;119(2):319\u201327.","journal-title":"Thromb Haemost"},{"issue":"15","key":"821_CR31","doi-asserted-by":"publisher","first-page":"e034412","DOI":"10.1161\/JAHA.124.034412","volume":"13","author":"K Kaneda","year":"2024","unstructured":"Kaneda K, Yamashita Y, Morimoto T, Chatani R, Nishimoto Y, Ikeda N, et al. Temporal changes in Long-Term outcomes of venous thromboembolism from the warfarin era to the direct oral anticoagulant era. J Am Heart Assoc. 2024;13(15):e034412.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"821_CR32","doi-asserted-by":"publisher","first-page":"22437","DOI":"10.1038\/s41598-022-26947-9","volume":"12","author":"Y Yamashita","year":"2022","unstructured":"Yamashita Y, Morimoto T, Kadota K, Takase T, Hiramori S, Kim K, et al. Clinical characteristics, management strategies and outcomes of patients with recurrent venous thromboembolism in the real world. Sci Rep. 2022;12(1):22437.","journal-title":"Sci Rep"},{"issue":"6","key":"821_CR33","doi-asserted-by":"publisher","first-page":"e023907","DOI":"10.1161\/JAHA.121.023907","volume":"11","author":"V Bayer","year":"2022","unstructured":"Bayer V, Kotalczyk A, Kea B, Teutsch C, Larsen P, Button D, et al. Global oral anticoagulation use varies by region in patients with recent diagnosis of atrial fibrillation: the GLORIA-AF phase III registry. J Am Heart Assoc. 2022;11(6):e023907.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"821_CR34","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1253\/circj.CJ-17-1128","volume":"82","author":"Y Yamashita","year":"2018","unstructured":"Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, et al. Anticoagulation therapy for venous thromboembolism in the real world \u2015 from the COMMAND VTE registry \u2015. Circ J. 2018;82(5):1262\u201370.","journal-title":"Circ J"},{"issue":"4","key":"821_CR35","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.itjm.2011.07.002","volume":"5","author":"P Di Micco","year":"2011","unstructured":"Di Micco P, Bura-Riviere A, Poggio R, Tiraferri E, Quintavalla R, Vison\u00e0 A, et al. Clinical characteristics of Italian patients with venous thromboembolism enrolled in the RIETE registry. Ital J Med. 2011;5(4):255\u201360.","journal-title":"Ital J Med"},{"issue":"1","key":"821_CR36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1744-8603-7-36","volume":"7","author":"FG De Maio","year":"2011","unstructured":"De Maio FG. Understanding chronic non-communicable diseases in Latin america: towards an equity-based research agenda. Glob Health. 2011;7(1):36.","journal-title":"Glob Health"},{"issue":"1","key":"821_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12939-021-01426-1","volume":"20","author":"AL Ruano","year":"2021","unstructured":"Ruano AL, Rodr\u00edguez D, Rossi PG, Maceira D. Understanding inequities in health and health systems in Latin America and the caribbean: a thematic series. Int J Equity Health. 2021;20(1):94.","journal-title":"Int J Equity Health"},{"issue":"8","key":"821_CR38","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1377\/hlthaff.2015.1366","volume":"35","author":"J Macinko","year":"2016","unstructured":"Macinko J, Guanais FC, Mullachery P, Jimenez G. Gaps in primary care and health system performance in six Latin American and Caribbean countries. Health Aff Proj Hope. 2016;35(8):1513\u201321.","journal-title":"Health Aff Proj Hope"},{"key":"821_CR39","doi-asserted-by":"crossref","unstructured":"Kornej J, B\u00f6rschel CS, Benjamin EJ, Schnabel RB. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ Res 2020 June 19;127(1):4\u201320.","DOI":"10.1161\/CIRCRESAHA.120.316340"},{"key":"821_CR40","unstructured":"CDC. Venous Thromboembolism (Blood Clots). 2025 [cited 2025 Nov 18]. Data and Statistics on Venous Thromboembolism. Available from: https:\/\/www.cdc.gov\/blood-clots\/data-research\/facts-stats\/index.html"},{"key":"821_CR41","doi-asserted-by":"crossref","unstructured":"Elliott AD, Middeldorp ME, Van Gelder IC, Albert CM, Sanders P. Epidemiology and modifiable risk factors for atrial fibrillation. Nat Rev Cardiol. 2023 June;20(6):404\u201317.","DOI":"10.1038\/s41569-022-00820-8"},{"issue":"16","key":"821_CR42","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.jacc.2024.07.014","volume":"84","author":"JJ Noubiap","year":"2024","unstructured":"Noubiap JJ, Tang JJ, Teraoka JT, Dewland TA, Marcus GM. Minimum National prevalence of diagnosed atrial fibrillation inferred from California acute care facilities. J Am Coll Cardiol. 2024;84(16):1501\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"821_CR43","first-page":"1787","volume":"17","author":"MS Marcolino","year":"2015","unstructured":"Marcolino MS, Palhares DMF, Benjamin EJ, Ribeiro AL. Atrial fibrillation: prevalence in a large database of primary care patients in Brazil. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol. 2015;17(12):1787\u201390.","journal-title":"Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol"},{"key":"821_CR44","first-page":"101110","volume":"47","author":"JG Andrade","year":"2025","unstructured":"Andrade JG, Jackson LR, Diaz JC, Chung M, Hurwitz J, Morillo CA, et al. Atrial fibrillation in the Americas. Lancet Reg Health - Am. 2025;47:101110.","journal-title":"Lancet Reg Health - Am"},{"issue":"4","key":"821_CR45","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/jth.13974","volume":"16","author":"PL Lutsey","year":"2018","unstructured":"Lutsey PL, Norby FL, Alonso A, Cushman M, Chen LY, Michos ED, et al. Atrial fibrillation and venous thromboembolism: evidence of bidirectionality in the atherosclerosis risk in communities study. J Thromb Haemost. 2018;16(4):670\u20139.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"821_CR46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamacardio.2018.4537","volume":"4","author":"J Gregson","year":"2019","unstructured":"Gregson J, Kaptoge S, Bolton T, Pennells L, Willeit P, Burgess S, et al. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol. 2019;4(2):163\u201373.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"821_CR47","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"GYH Lip","year":"2011","unstructured":"Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation. JACC. 2011;57(2):173\u201380.","journal-title":"JACC"},{"issue":"12","key":"821_CR48","doi-asserted-by":"publisher","first-page":"e017157","DOI":"10.1136\/bmjopen-2017-017157","volume":"7","author":"KAA Fox","year":"2017","unstructured":"Fox KAA, Lucas JE, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, et al. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 2017;7(12):e017157.","journal-title":"BMJ Open"},{"issue":"2","key":"821_CR49","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GYH Lip","year":"2010","unstructured":"Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk Factor-Based approach: the Euro heart survey on atrial fibrillation. Chest. 2010;137(2):263\u201372.","journal-title":"Chest"},{"issue":"5","key":"821_CR50","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","volume":"154","author":"GYH Lip","year":"2018","unstructured":"Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121\u2013201.","journal-title":"Chest"},{"issue":"1","key":"821_CR51","doi-asserted-by":"publisher","first-page":"e0317895","DOI":"10.1371\/journal.pone.0317895","volume":"20","author":"GYH Lip","year":"2025","unstructured":"Lip GYH, Benamouzig R, Martin AC, Pesce G, Gusto G, Quignot N, et al. Comparative safety and effectiveness of oral anticoagulants in key subgroups of patients with non-valvular atrial fibrillation and at high risk of Gastrointestinal bleeding: A cohort study based on the French National health data system (SNDS). PLoS ONE. 2025;20(1):e0317895.","journal-title":"PLoS ONE"},{"key":"821_CR52","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1146\/annurev-pharmtox-032823-122811","volume":"64","author":"RH Olie","year":"2024","unstructured":"Olie RH, Winckers K, Rocca B, Ten Cate H. Oral anticoagulants beyond warfarin. Annu Rev Pharmacol Toxicol. 2024;64:551\u201375.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"11","key":"821_CR53","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1080\/03007995.2018.1467885","volume":"34","author":"AJ Camm","year":"2018","unstructured":"Camm AJ, Fox KAA. Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for Rivaroxaban. Curr Med Res Opin. 2018;34(11):1945\u201357.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"821_CR54","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s00392-021-01957-1","volume":"111","author":"MV Huisman","year":"2022","unstructured":"Huisman MV, Teutsch C, Lu S, Diener HC, Dubner SJ, Halperin JL, et al. Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from phase III of the GLORIA-AF registry. Clin Res Cardiol. 2022;111(5):548\u201359.","journal-title":"Clin Res Cardiol"},{"key":"821_CR55","doi-asserted-by":"publisher","unstructured":"Jeong J, Heo KN, Lee S, Ah YM, Min S, Han JM et al. Exploring bleeding in oral anticoagulant users: assessing incidence by indications and risk factors in the entire nationwide cohort. Front Pharmacol [Internet]. 2024 Sept 19 [cited 2025 July 3];15. Available from: https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/https:\/\/doi.org\/10.3389\/fphar.2024.1399955\/full","DOI":"10.3389\/fphar.2024.1399955\/full"},{"key":"821_CR56","doi-asserted-by":"crossref","unstructured":"Kohsaka S, Katada J, Saito K, Terayama Y. Safety and effectiveness of Apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data. Curr Med Res Opin. 2018 Sept;34(9):1627\u201334.","DOI":"10.1080\/03007995.2018.1478282"},{"issue":"11","key":"821_CR57","doi-asserted-by":"publisher","first-page":"e0242922","DOI":"10.1371\/journal.pone.0242922","volume":"15","author":"OY Bang","year":"2020","unstructured":"Bang OY, On YK, Lee MY, Jang SW, Han S, Han S, et al. The risk of stroke\/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: results from a real-world data analysis. PLoS ONE. 2020;15(11):e0242922.","journal-title":"PLoS ONE"},{"issue":"6","key":"821_CR58","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","volume":"139","author":"N van Rein","year":"2019","unstructured":"van Rein N, Heide-J\u00f8rgensen U, Lijfering WM, Dekkers OM, S\u00f8rensen HT, Cannegieter SC. Major bleeding rates in atrial fibrillation patients on Single, Dual, or triple antithrombotic therapy. Circulation. 2019;139(6):775\u201386.","journal-title":"Circulation"},{"issue":"11","key":"821_CR59","first-page":"1760","volume":"60","author":"ZM Dimitrijevic","year":"2024","unstructured":"Dimitrijevic ZM, Mitic BP, Tasic DD, Vrecic T, Paunovic K, Salinger S. Bleeding and thrombotic events in Hemodialysis patients with atrial fibrillation on anticoagulation and antiplatelet therapy: A 24-Month cohort study. Med (Mex). 2024;60(11):1760.","journal-title":"Med (Mex)"},{"issue":"1","key":"821_CR60","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/ehjcvp\/pvw031","volume":"3","author":"S Halvorsen","year":"2017","unstructured":"Halvorsen S, Ghanima W, Fride Tvete I, Hoxmark C, Falck P, Solli O, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J \u2014 Cardiovasc Pharmacother. 2017;3(1):28\u201336.","journal-title":"Eur Heart J \u2014 Cardiovasc Pharmacother"},{"key":"821_CR61","doi-asserted-by":"crossref","unstructured":"Pollack CV, Peacock WF, Bernstein RA, Clark CL, Douketis J, Fermann GJ et al. The safety of oral anticoagulants registry (SOAR): A national, ED-based study of the evaluation and management of bleeding and bleeding concerns due to the use of oral anticoagulants. Am J Emerg Med. 2020 June 1;38(6):1163\u201370.","DOI":"10.1016\/j.ajem.2019.12.023"},{"issue":"2","key":"821_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40138-013-0014-6","volume":"1","author":"M Alquwaizani","year":"2013","unstructured":"Alquwaizani M, Buckley L, Adams C, Fanikos J, Anticoagulants. A review of the Pharmacology, Dosing, and complications. Curr Emerg Hosp Med Rep. 2013;1(2):83\u201397.","journal-title":"Curr Emerg Hosp Med Rep"},{"issue":"10","key":"821_CR63","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1111\/jth.15466","volume":"19","author":"Y Xu","year":"2021","unstructured":"Xu Y, Siegal DM. Anticoagulant-associated Gastrointestinal bleeding: framework for decisions about whether, when and how to resume anticoagulants. J Thromb Haemost. 2021;19(10):2383\u201393.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"821_CR64","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3390\/ph18020170","volume":"18","author":"J Last","year":"2025","unstructured":"Last J, Birschmann I, Lindau S, Konstantinides S, Grottke O, Nowak-G\u00f6ttl U, et al. Anticoagulant management after emergency surgery or major bleeding in anticoagulated Patients\u2014Results of the prospective RADOA registry. Pharmaceuticals. 2025;18(2):170.","journal-title":"Pharmaceuticals"},{"issue":"10","key":"821_CR65","doi-asserted-by":"publisher","first-page":"e085401","DOI":"10.1136\/bmjopen-2024-085401","volume":"14","author":"RD Giorno","year":"2024","unstructured":"Giorno RD, Mazzolai L, Keller S, Siniscalchi C, Lopez-Jimenez L, Ballaz A, et al. Assessment of bleeding events in patients receiving DOACs with or without Statins to treat venous thromboembolism: insights from the RIETE registry. BMJ Open. 2024;14(10):e085401.","journal-title":"BMJ Open"},{"key":"821_CR66","doi-asserted-by":"crossref","unstructured":"Cools F, Johnson D, Camm AJ, Bassand J, Verheugt FWA, Yang S, et al. Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: results from the GARFIELD-AF registry. J Thromb Haemost. 2021 Sept;19(9):2322\u201334.","DOI":"10.1111\/jth.15415"},{"key":"821_CR67","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.thromres.2023.08.016","volume":"230","author":"G Chu","year":"2023","unstructured":"Chu G, Seelig J, Cannegieter SC, Gelderblom H, Hovens MMC, Huisman MV, et al. Thromboembolic and bleeding complications during interruptions and after discontinuation of anticoagulant treatment in patients with atrial fibrillation and active cancer: A daily practice evaluation. Thromb Res. 2023;230:98\u2013104.","journal-title":"Thromb Res"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-025-00821-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00821-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00821-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T08:06:52Z","timestamp":1768464412000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12959-025-00821-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["821"],"URL":"https:\/\/doi.org\/10.1186\/s12959-025-00821-w","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol (Protocol No. 1293) was reviewed and approved by the CEIB of the FVL, Cali, Colombia, as documented in Resolution No. 19 dated September 26, 2018, and Letter No. 283\u20132018. The protocol was also approved by the ethics committees of all participating institutions. Patient consent was waived by the CEIB, as no interventions were performed and all information was obtained from patients\u2019 usual clinical practice. Anonymization of all personal information was ensured.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Artificial intelligence programs (large language models) were used for proofreading and spell check.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of artificial intelligence"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}